Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

September 22, 2028

Study Completion Date

September 22, 2028

Conditions
Age-related Macular Degeneration (ARMD)Choroidal NeovascularizationAnti-vascular Endothelial Growth Factor
Interventions
DRUG

Intravitreal faricimab injection

"* Initial loading injections : every 4 weeks by 12weeks~* Treat and extend injection(\~76 week) : Week 20 - Week 76~TAE is initiated with a minimum injection interval of 8 weeks. If no recurrence is observed, the interval is extended by 2 weeks at a time, up to a maximum of 16 weeks. In the event of recurrence, the injection interval is reduced to 8 weeks, regardless of the previous schedule. The minimum injection interval remains 8 weeks."

Trial Locations (1)

150-034

Kim's Eye Hospital, Seoul

All Listed Sponsors
lead

Kim's Eye Hospital

OTHER